Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
000-0551 Lotion in Plaque Psoriasis
NCT01871402Phase 3Completed
- Start
- May 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Halobetasol propionate 0.05% lotion in plaque psoriasis (2 arms). Primary endpoint: Proportion of Subjects Rated a 'Treatment Success' Based on the Investigator's Global Assessment at Day 15. Started May 2013; status: completed.
02
Drugs
Halobetasol propionate 0.05% lotion
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01871402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01871402.